| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Virology, December 2007, p. 13771-13782, Vol. 81, No. 24
0022-538X/07/$08.00+0 doi:10.1128/JVI.01313-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Jürgen Soutschek,3,
Zsolt Ruzsics,1
Ulrich Koszinowski,1
Olivier Voinnet,2 and
Sébastien Pfeffer2*
Max von Pettenkofer-Institut für Virologie, Ludwig-Maximilians-Universität München, Pettenkoferstr. 9a, 80336 München, Germany,1 IBMP-CNRS, 12, rue du Général Zimmer, 67084 Strasbourg Cedex, France,2 Alnylam Europe AG, Fritz-Hornschuch-Str. 9, 95326 Kulmbach, Germany3
Received 15 June 2007/ Accepted 3 October 2007
MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate gene expression at the posttranscriptional level. Originally identified in a variety of organisms ranging from plants to mammals, miRNAs have recently been identified in several viruses. Viral miRNAs may play a role in modulating both viral and host gene expression. Here, we report on the identification and characterization of 18 viral miRNAs from mouse fibroblasts lytically infected with the murine cytomegalovirus (MCMV). The MCMV miRNAs are expressed at early times of infection and are scattered in small clusters throughout the genome with up to four distinct miRNAs processed from a single transcript. No significant homologies to human CMV-encoded miRNAs were found. Remarkably, as soon as 24 h after infection, MCMV miRNAs constituted about 35% of the total miRNA pool, and at 72 h postinfection, this proportion was increased to more than 60%. However, despite the abundance of viral miRNAs during the early phase of infection, the expression of some MCMV miRNAs appeared to be regulated. Hence, for three miRNAs we observed polyuridylation of their 3' end, coupled to subsequent degradation. Individual knockout mutants of two of the most abundant MCMV miRNAs, miR-m01-4 and miR-M44-1, or a double knockout mutant of miR-m21-1 and miR-M23-2, incurred no or only a very mild growth deficit in murine embryonic fibroblasts in vitro.
Published ahead of print on 17 October 2007.
Present address: Roche Kulmbach GmbH, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
Present address: Regulus Therapeutics, 1896 Rutherford Road, Carlsbad, CA 92008-7208.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|